RSVP Here

Speakers: Shelia Violette and Christopher Garbe

• Shelia Violette, PhD
  CSO of Admirx

  • Shelia M. Violette, Ph.D., is the CSO of Admirix and has been an Entrepreneur in Residence at Atlas Venture since 2017. Dr. Violette served as Vice President of Tissue Injury and Fibrosis at Biogen-Idec., where she spearheaded a team of scientists conducting discovery research and developing translational approaches to advance programs into clinical development. Dr. Violette has more than 20 years of experience in drug development, advancing programs from early stage research to clinical development. This has included studying the role of the alphavbeta6 integrin in many forms of tissue injury and fibrosis and developing a humanized monoclonal antibody that is in clinical development. Prior to Biogen-Idec, she served as Vice President of Research at Stromedix, Inc. from 2008 to 2012 and led all research activities supporting the development of the anti-v6 antibody, STX-100. She has been Member of Scientific Advisory Board at Scholar Rock, Inc. since May 25, 2017. She served as Director in Immunology at Biogen Idec and previously the Research Head for the Fibrosis. She also worked at ARIAD Pharmaceuticals and Repligen. Dr. Violette serves as a Member of Scientific Advisory Board at Morphic Rock Therapeutic, Inc. She has provided strategic and operational leadership to multi-disciplinary teams of scientists and authored more than 80 manuscripts and patents. Dr. Violette has directed research and led therapeutic programs at several biotechnology companies including Repligen, Ariad, Stromedix and Biogen.

    She has a BS from Massachusetts College of Pharmacy in 1983 and a PhD in pharmacology from Yale University in 1989. She carried out her post-doctoral training with Frank Ruddle in the Department of Biology at Yale University.
    
    

• Christopher Garbe, MS MBA
  Director of Quality  Charles C. Gates Biomanufacturing Facility
  

  • 20+ years’ experience in the design, qualification and operation of process/analytical development and quality control labs in a cGMP setting
  • Leader in internal and external Quality operations for start-up and large pharmaceutical organizations to support recombinant protein, nucleic acid and cellular therapy (CAR-T, TCR, cord blood) products as they progress from pre-IND to clinical trials through commercial approval
  • Responsible for the translation and technology transfer of multiple drug substance and drug product manufacture and quality operations within academic, industrial and contract manufacturing settings
  • Author of numerous Chemistry, Manufacturing and Control regulatory submissions to support IND/BLA/MAA applications and post-marketing approvals
  • B.S. in Chemistry from Rensselear Polytechnic Institute, M.S. in Biochemistry and Molecular Biology from George Washington University, M.B.A. from McCombs School of Business – University of Texas – Austin